在一項涉及了50000例患者的新藥臨床試驗中，發現價格便宜的抗血小板藥物將clopidogrel添加到標準治療之中，能夠將心臟病發作患者入院治療1周后發生其它動脈阻塞或者心臟病二次發作的幾率降低了36％，

在該項臨床試驗中患者有急性ST段升高的心肌缺血性梗死（STEMI）。在30天之后clopidogrel把心血管源性死亡、心肌梗死再發以及導致緊急血管再造的再發性缺血減少了20％。這項試驗發現無論患者性別、接受的標準治療方案（纖維蛋白溶解類型或者肝素類型）或者心臟病發作的部位有何不同，結果都保持一致。

另外一項相同的臨床試驗發現：除了標準治療方案之外，使用clopidogrel治療心臟病發作患者，把死亡的相對危險降低了7％，心臟病復發的危險降低了9％。英國牛津大學Zheng Ming Chen醫生說：“這項臨床試驗還顯示：治療并不會顯著增加胎兒的風險或者與clopiogrel治療相關的輸血出血風險。”Zheng Ming Chen醫生在2005年3月美國奧蘭多(FL, USA)舉行的美國心臟病學院年會上報道了這些試驗結果。

其它參與該項臨床試驗的研究人員分別來自哈佛醫學院(Boston, MA, USA)、Brigham與婦女醫院(Boston, MA, USA)、中國北京阜外醫院以及中國醫學科學院。重大出血與顱內出血發生率在兩個治療組中類似。Clopidogrel(clopidogrel bisulfate)在全球范圍內是由Sanofi-Aventis公司 (Paris, France)和Bristol-Myers Squibb 公司 (Princeton, NJ, USA)推向市場的，名稱分別是Plavix與Iscover。
 
Drug Improves Heart-Attack Survival
 
One trial in a new study involving nearly 50,000 patients has shown that the inexpensive anti-platelet agent clopidogrel added to standard therapy reduced the odds of heart attack patients having another occluded artery or a second heart attack by 36% after one week of hospitalization.

Patients in the study had acute ST-segment elevation myocardial infarction (STEMI). After 30 days, clopidogrel reduced the odds of cardiovascular death, recurrent infarction, and recurrent ischemia leading to urgent revascularization by 20%. The results were consistent regardless of gender, the standard therapy received (type of fibrinolytic or type of heparin), or the location of the heart attack.

Another trial in the same study found that treating heart attack patients with clopidogrel in addition to standard therapy reduced the relative risk of death by 7% and the risk of a recurrent heart attack by 9%. “The study also showed that there was no significant increase in the risk of fetal or transfused bleeding associated with clopidogrel therapy,” said Zheng Ming Chen, M.D., University of Oxford (UK), who presented the findings at the annual meeting of the American College of Cardiology in Orlando (FL, USA) in March 2005.

Other researchers who took part in the study were from Harvard Medical School (Boston, MA, USA), Brigham and Women’s Hospital (also in Boston), and Fuwai Hospital and the Chinese Academy of Medical Sciences (both in Beijing, China). The rates of major bleeding and intracranial hemorrhage were similar in both treatment groups. Clopidogrel (clopidogrel bisulfate) is marketed worldwide by Sanofi-Aventis (Paris, France) and Bristol-Myers Squibb Company (Princeton, NJ, USA) as Plavix and Iscover.